The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma.
作者信息
Kim Beom Kyung
机构信息
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Gut Liver. 2024 Jan 15;18(1):3-4. doi: 10.5009/gnl230505.
Abstract
摘要
相似文献
1
The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma.多激酶抑制剂在肝细胞癌免疫检查点抑制剂时代的地位
Gut Liver. 2024 Jan 15;18(1):3-4. doi: 10.5009/gnl230505.
2
Pursuing efficacious systemic therapy for hepatocellular carcinoma.寻求针对肝细胞癌的有效全身治疗方法。
Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):95-96. doi: 10.1038/s41575-020-00405-1.
3
Oral chemotherapy for the treatment of hepatocellular carcinoma.口服化疗药物治疗肝细胞癌。
Expert Opin Pharmacother. 2018 Jun;19(9):993-1001. doi: 10.1080/14656566.2018.1479398. Epub 2018 Jun 18.
4
Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.用于肝细胞癌治疗的免疫刺激单克隆抗体。趋势与展望。
Medicina (B Aires). 2018;78(1):29-32.
5
Treatment options after sorafenib failure in patients with hepatocellular carcinoma.索拉非尼治疗失败后肝癌患者的治疗选择。
Clin Mol Hepatol. 2017 Dec;23(4):273-279. doi: 10.3350/cmh.2017.0108. Epub 2017 Nov 20.
6
Targeted therapy for hepatocellular carcinoma.肝细胞癌的靶向治疗。
Signal Transduct Target Ther. 2020 Aug 11;5(1):146. doi: 10.1038/s41392-020-00264-x.
7
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.索拉非尼：晚期肝细胞癌及其他病症的金标准疗法。
Future Oncol. 2015;11(16):2263-6. doi: 10.2217/fon.15.161.
8
Review article: systemic treatment of hepatocellular carcinoma.综述文章：肝细胞癌的系统治疗。
Aliment Pharmacol Ther. 2018 Sep;48(6):598-609. doi: 10.1111/apt.14913. Epub 2018 Jul 23.
9
Regorafenib as treatment for patients with advanced hepatocellular cancer.瑞戈非尼治疗晚期肝细胞癌。
Future Oncol. 2017 Oct;13(25):2223-2232. doi: 10.2217/fon-2017-0204. Epub 2017 Aug 2.
10
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.当前靶向治疗对肝细胞癌的免疫调节作用：对免疫治疗未来的启示。
Semin Liver Dis. 2018 Nov;38(4):379-388. doi: 10.1055/s-0038-1673621. Epub 2018 Oct 24.
本文引用的文献
1
The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.乐伐替尼在肝细胞癌免疫治疗时代的作用。
J Liver Cancer. 2023 Sep;23(2):262-271. doi: 10.17998/jlc.2023.07.17. Epub 2023 Aug 17.
2
Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea.索拉非尼治疗 9923 例肝细胞癌患者的疗效：来自韩国国家健康保险索赔数据的分析。
Gut Liver. 2024 Jan 15;18(1):116-124. doi: 10.5009/gnl220406. Epub 2023 Jun 19.
3
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment.仑伐替尼在肝细胞癌一线治疗新时代的不断演变的角色。
Clin Mol Hepatol. 2023 Oct;29(4):909-923. doi: 10.3350/cmh.2023.0114. Epub 2023 May 25.
4
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective.肝细胞癌的临床实践指南与实际临床实践：韩国视角。
Clin Mol Hepatol. 2023 Apr;29(2):197-205. doi: 10.3350/cmh.2022.0404. Epub 2023 Jan 5.
5
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.2022 KLCA-NCC 韩国肝细胞癌管理实践指南。
Clin Mol Hepatol. 2022 Oct;28(4):583-705. doi: 10.3350/cmh.2022.0294. Epub 2022 Oct 1.
6
Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma.纳武利尤单抗联合索拉非尼治疗不可切除肝细胞癌患者的疗效
Int Immunopharmacol. 2022 Nov;112:109223. doi: 10.1016/j.intimp.2022.109223. Epub 2022 Sep 7.
7
Systemic treatment of hepatocellular carcinoma: An EASL position paper.肝细胞癌的全身治疗：一篇欧洲肝脏研究学会立场文件。
J Hepatol. 2021 Oct;75(4):960-974. doi: 10.1016/j.jhep.2021.07.004. Epub 2021 Jul 10.
8
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study.一线阿替利珠单抗联合贝伐单抗治疗进展后使用多激酶抑制剂治疗晚期肝细胞癌患者的临床结局：一项多国多中心回顾性研究
Liver Cancer. 2021 Apr;10(2):107-114. doi: 10.1159/000512781. Epub 2021 Mar 3.
9
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.索拉非尼永久停药的晚期肝细胞癌患者生存的预测因素。
Hepatology. 2015 Sep;62(3):784-91. doi: 10.1002/hep.27729. Epub 2015 Mar 20.
Zotero 插件